• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

byBoaz WongandHarsh Shah
May 13, 2022
in Infectious Disease, Obstetrics, Obstetrics and Gynecology Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The prefusion F protein of RSV (RSVpreF) vaccine produces neutralizing antibodies against RSV in both the serum of the pregnant mother and successful transplacental transfer to the infant.

2. Non-aluminum formulations of the RSVpreF vaccine produced fewer adverse side effects and greater transplacental neutralizing antibodies compared to aluminum formulations.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Respiratory syncytial virus (RSV) infection is a major cause of infant hospitalization death worldwide. To combat this, a vaccine designed against the prefusion F protein of RSV (RSVpreF vaccine) can be administrated to pregnant women in the late second or third trimester of pregnancy. The objective of this phase 2b randomized control trial was to evaluate the safety and immunogenicity of the vaccines, as well as confirm the transplacental transfer of RSV neutralizing antibodies. Healthy pregnant women between 24-36 weeks gestation were randomized in a 1:1:1:1:1 ratio to receive either an intramuscular low dose of RSVpreF without aluminum hydroxide, high dose without aluminum, low dose with aluminum, high dose with aluminum, or placebo. The primary endpoints were a safety that followed adverse events to either the mother or the infants, immunogenicity which was the quantity of RSV titers and neutralizing antibodies, and transplacental transfer ratios of the neutralizing antibodies. The study found that most patients only experience mild to moderate reactions to vaccination and were higher in those receiving the aluminum formulation. No significant differences in adverse event incidence were found between the vaccine and placebo groups. Analysis of samples of serum and umbilical blood in patients receiving the vaccine detected RSV A and B neutralizing antibodies, but transplacental neutralizing antibody transfer ratios were higher in the non-aluminum formulation. Overall, this study confirms the safety and immunogenicity of the RSVpreF vaccine. Limitations of this study include its exclusive enrolment of Americans, limiting its generalizability, as well as a lack of follow-up on antibody titers following the birth or throughout infant development. Efficacy will formally be assessed in the subsequent phase 3 trial.

Click to read the study in NEJM 

Relevant Reading: Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

In-Depth [randomized controlled trial]: In this multi-center, observed-blinded, placebo-controlled, phase 2b randomized control trial, 406 women and 403 infants were randomized in a 1:1:1:1:1 ratio to receive, by intramuscular injection, either 120 μg or 240 μg RSVpreF vaccine, formulated with or without aluminum hydroxide, or placebo, respectively. Eligible patients were healthy pregnant women at 24-36 weeks gestation. The primary objective was to evaluate the safety and immunogenicity of the vaccine ahead of its phase 3 efficacy trial. Maternal blood was drawn before vaccination, between delivery, at delivery, and up to 6 months after delivery. Umbilical cord blood was also collected, and infant blood is drawn up to 6 months after birth. Drawn blood was analyzed for immunogenicity endpoints including 50% titers of RSV and neutralizing antibodies. For the primary safety endpoint, patients and their infants were followed for adverse side effects via an electronic diary. 80.5% of the entire cohort received the RSVpreF vaccine, most of which only experience mild to moderate side effects including injection site reaction and moderate pain. Notably, patients receiving the vaccine with aluminum formulation reported side effects at a higher frequency. No differences were reported with respect to adverse side effects related to vaccination between all groups. While serious adverse events were experienced at delivery or shortly after, none were considered to be significantly linked to vaccination. With respect to immunogenicity, 50% geometric mean titers of RSV A neutralizing antibodies ranged from 11.0 – 15.1, and for RSV B neutralizing antibodies ranged from 13.7 – 17.5, indicating their presence in maternal blood. In umbilical-cord blood, RSV A neutralizing antibodies ranged from 9.7 – 11.7 and 13.6 – 16.8 for RSV B neutralizing antibodies. Corresponding transplacental transfer ratios were between 1.68 – 2.1 in groups without aluminum hydroxide formulation and 1.41 – 1.67 with aluminum. Overall, this study support that the RSVpreF vaccine induces RSV neutralizing antibodies in both the maternal and infant blood, supporting its exploration in a phase 3 efficacy trial.

RELATED REPORTS

The Scan by 2 Minute Medicine®: the New Cost of Insulin, Beyond IVF, the Spotlight on RSV and Influenza, and Theranos Founder Sentenced to 11 Years!

Regular physical activity may improve vaccine effectiveness against COVID-19 outcomes

Wellness Check: Exercise

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antibodiesneutralizing antibodiesrespiratory syncytial virus (RSV)RSVRSV fusion proteintransplacentalvaccine
Previous Post

CT associated with lower complication risks than invasive coronary angiography

Next Post

Fourth BNT162b2 vaccine dose provides short-term effectiveness against Covid-19 related outcomes

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: the New Cost of Insulin, Beyond IVF, the Spotlight on RSV and Influenza, and Theranos Founder Sentenced to 11 Years!

November 30, 2022
Reduced gestational weight gain with lifestyle intervention
Chronic Disease

Regular physical activity may improve vaccine effectiveness against COVID-19 outcomes

November 28, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Wellness

Wellness Check: Exercise

November 24, 2022
Infectious Disease

COVID-19 vaccine associated with temporary decreased rates of successful in-vitro fertilization following vaccination

November 9, 2022
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

Fourth BNT162b2 vaccine dose provides short-term effectiveness against Covid-19 related outcomes

Low evidence for glycerin use in preterm infants

Nasal high-flow therapy improves likelihood of neonatal intubation

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Dapagliflozin efficacious and safe in treating heart failure

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options